Centessa Pharmaceuticals PLC

Centessa Pharmaceuticals — Investor Presentation (September 2022)

27 slides from Centessa Pharmaceuticals's investor presentation, Sep 12, 2022

  1. Slide 1: Corporate Overview: Asset-Centric. Patient-Centric.

    Corporate Overview Asset-Centric. Patient-Centric.

  2. Slide 2: Disclaimer and forward-looking statements

    This presentation has been prepared by Centessa Pharmaceuticals plc (the “Company”) for informational purposes only and not for any other purpose. This presentation does not contain all the information that is or may be material to investors or potential investors and should not be considered as adv

  3. Slide 3: Discovering and developing medicines that are truly transformational for patients

    Discovering and developing medicines that are truly transformational for patients Multiple potential blockbuster assets with clinical readouts anticipated over next two years Cash runway into 2026 enables clinical proof of concept readouts across portfolio World-class R&D team 3Note: $484.2 million

  4. Slide 4: A transformational pharmaceutical company fueling an innovative pipeline

    DIFFERENTIATION We are a transformational pharmaceutical company fueling an innovative pipeline 4 Lead Assets Disease Estimated Market Size* SerpinPC Hemophilia B $2B+1 LB101 Solid Tumors $10B1 MGX292 Pulmonary Arterial Hypertension (PAH) $6B1 OX2R Agonists Narcolepsy (NT1) $2B+1 MULTIPLE PATHWAYS T

  5. Slide 5: Cash runway into 2026 enables clinical proof of concept readouts across pipeline

    PRE-CLINICAL PHASE 1 PHASE 2 REGISTRATIONAL SerpinPC in Hemophilia (Hemophilia B Registrational Trial) LB101 in Solid Tumors MGX292 in Pulmonary Arterial Hypertension (PAH) OX2R Agonists in Narcolepsy (NT1) CBS001 in Inflammatory/ Fibrotic Diseases CBS004 in Systemic Sclerosis, Lupus Erythematosus 2

  6. Slide 6: Team with deep R&D experience focused on execution

    LEADERSHIP Team with deep R&D experience focused on execution 6 THOMAS TEMPLEMAN PhD Chief Technology Officer DAVID CHAO PhD Chief Administrative Officer TIA BUSH Chief Quality Officer SAURABH SAHA MD PhD Chief Executive Officer ANTOINE YVER MD MSc EVP & Chairman of Development DAVID GRAINGER PhD Ch

  7. Slide 7: SerpinPC in Hemophilia

    SerpinPC in Hemophilia YK CENTESSA

  8. Slide 8: SerpinPC: Potential transformative therapy in hemophilia

    SerpinPC: Potential transformative therapy in hemophilia 8 Novel MoA; Non-factor approach Significant reduction in bleeding2 Potential best-in- class safety profile: No thrombosis observed2 Convenient subcutaneous dosing Inhibitor of APC designed to prevent and reduce bleeds without risk of thrombos

  9. Slide 9: SerpinPC is believed to have a unique MoA supported by human genetics

    SerpinPC is believed to have a unique MoA supported by human genetics 9 Primary APC is the target of SerpinPC All beds Spontaneous joint bleeds • Human genetic target validation • Engineered to specifically inhibit APC • Inhibition of APC increases thrombin • Feedback loop prevents excess thrombin g

  10. Slide 10: Phase 2a Study: SerpinPC showed significant reductions in bleeding rates

    Phase 2a Study: SerpinPC showed significant reductions in bleeding rates 10 One moderate skin reaction led to withdrawal of a subject with history of a skin disorder. Two subjects with ADAs, with no apparent impact on ABRs. No other SerpinPC-related AEs. ABR is annualized bleeding rate. Six-month up

  11. Slide 11: Phase 2a Study: Individual observed ABRs for all bleeds and spontaneous joint bleeds

    Phase 2a Study: Individual observed ABRs for all bleeds and spontaneous joint bleeds 11 All bleeds ABR Spontaneous joint bleeds ABR Six-month update of Phase 2a Study. ABR is annualized bleeding rate. 1. During second 12 weeks of exposure (as prespecified in the statistical analysis plan). Once mont

  12. Slide 12: Phase 2a Study: Individual observed ABRs across dose cohorts

    Phase 2a Study: Individual observed ABRs across dose cohorts 12Six-month update of Phase 2a Study. ABR is annualized bleeding rate. 1. During second 12 weeks of exposure (as prespecified in the statistical analysis plan). Once monthly injections. -60 -40 -20 0 20 40 60 0.3 mg/kg 1.2 mg/kg 0.6 mg/kg

  13. Slide 13: Registrational study design for hemophilia B

    13 1.2 mg/kg SC Q1W n=20 1.2 mg/kg SC Q2W n=20 1.2 mg/kg SC Q4W n=20 Part 1 (24 weeks) Randomized Dose Justification Phase Prophylaxis cohort: n=30 (HemB ≥15) 12-week observation period Part 2 (24 weeks) Efficacy/safety assessment Part 3 (24 weeks) Additional efficacy/safety data Subjects from Part

  14. Slide 14: LB101 in Solid Tumors

    LB101 in Solid Tumors 14

  15. Slide 15: LB101: Potential first-in-class immunotherapy targeting solid tumors

    LockBody “It’s all about the hinge” LB101:Potential first-in-class immunotherapy targeting solid tumors 15 Pioneering our novel LockBody® pharmacology IND submission planned for late 2022; Additional LockBody candidates expected in 2023 S T A T U S : Novel pharmacology focused on human IgG- derived

  16. Slide 16: LB101: Designed to deliver anti-PD-L1 activity plus targeted anti-CD47 activity to the TME

    LB101: Designed to optimally deliver anti-PD-L1 activity plus targeted anti-CD47 activity to the TME 16 Tumor Unlocking: IgG1 hinges susceptible to cleavage in diseased tissue by various natural processes Peripheral Stability: IgG1 hinges naturally resistant to cleavage in serum Constitutive Fabs: P

  17. Slide 17: LB101 showed improved efficacy and durability over atezolizumab in a mouse model

    LB101 showed improved efficacy and durability over atezolizumab in a difficult-to-treat mouse model while being well tolerated 17 In vivo: Systemically delivered LB101 exhibited significant tumor regression In vivo: LB101 was well tolerated with no weight loss Note: MC38 hPD-L1+ syngeneic model in m

  18. Slide 18: LB101 shown to be safe and well tolerated in non-human primates

    LB101 shown to be safe and well tolerated in non-human primates 18 In-vivo: LB101 delivered IV at 5, 20, 50mg/kg (q7d x 4) in non-human primates • Human IgG1-like PK • No adverse observations - No impact on any hematology (no anemia or thrombocytopenia) - No changes in pathology, clinical chemistry

  19. Slide 19: MGX292 in Pulmonary Arterial Hypertension

    19 MGX292 in Pulmonary Arterial Hypertension

  20. Slide 20: MGX292: Potential for disease reversal in patients with PAH

    20 MGX292: Potential for disease reversal in patients with PAH Novel MoA with potential for disease reversal Designed to directly restore BMP9 signaling genetically missing or deficient in PAH and avoid undesired bone formation In vivo data demonstrated reversal of lung vascular pathology Protein-en

  21. Slide 21: Preclinical Data: MGX292 demonstrated dose-dependent reversal of lung vascular pathology

    Preclinical Data: MGX292 demonstrated dose- dependent reversal of established lung vascular pathology in Sugen-hypoxia rat model 1. MGX292 treatment was given daily for 4 weeks; 2. Red arrows depict vascular lesions MGX2921 reversed neointimal lesions in Sugen-hypoxia rat model of severe PAH 0 5 10

  22. Slide 22: OX2R Agonists in NT1

    OX2R Agonists in NT1 22

  23. Slide 23: OX2R Agonists: Potential to change the standard of care for narcolepsy

    Highly validated human genetic target Clinical proof of concept (PoC) for efficacy in NT1 and in other sleep/wake disorders3 23 OX2R Agonists: Potential to change the standard of care for narcolepsy High unmet need EDS is excessive daytime sleepiness. 1. Evaluate Pharma 2021. 2. Maski K, et al. J Cl

  24. Slide 24: Structure-based drug design has enabled discovery of OX2R agonists

    Structure-based drug design has enabled the discovery of OX2R agonists with potential as replacement therapy for NT1 The newest compounds have demonstrated sub-nanomolar potency in in vitro assays * Example X-ray structure of OX2R with small molecule orexin agonist (shown in purple) Example Cryo-EM

  25. Slide 25: Novel OX2R agonists increase wakefulness in WT and NT1 mice

    Novel OX2R agonists increase wakefulness in WT and NT1 mice Note: Wakefulness detected by piezoelectric monitoring, which is a rapid, non-invasive method for classifying sleep and wakefulness by unsupervised machine learning Exemplar small molecule agonists Exemplar peptide agonist 25 NT1 Mouse Mode

  26. Slide 26: Centessa is fueling multiple pathways to value creation

    Centessa is fueling multiple pathways to value creation 26 Multiple potential blockbuster assets with clinical readouts anticipated over next two years Cash runway into 2026 enables clinical proof of concept readouts across portfolio World-class R&D team Note: $484.2 million in cash and cash equival

  27. Slide 27: Centessa Pharmaceuticals

    << CENTESSA PHARMACEUTICALS

Centessa Pharmaceuticals — Investor Presentation (September 2022) on 6ix